文献速递乳腺癌

CHER-Lob试验:拉帕替尼联合曲妥珠单抗新辅助治疗HER2阳性早期乳腺癌的生存分析

Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial.
PubMed 文献 · Eur J Cancer · 2021-06-19

CHER-Lob随机II期研究纳入121例HER2阳性II-IIIA期乳腺癌患者,比较拉帕替尼联合曲妥珠单抗联合化疗与曲妥珠单抗或拉帕替尼联合化疗的疗效。中位随访9年,拉帕替尼联合曲妥珠单抗较曲妥珠单抗显示无复发生存改善趋势(HR 0.44,95%CI 0.18-1.05);pCR与RFS和OS均显著相关(HR均为0.12,95%CI 0.03-0.49)。

要点

  • 拉帕替尼联合曲妥珠单抗较曲妥珠单抗显示RFS改善趋势(HR 0.44,95%CI 0.18-1.05)。
  • pCR与RFS和OS均显著相关,HR均为0.12(95%CI 0.03-0.49)。
  • TILs每增加1%与RFS显著相关(HR 0.978),Luminal-A亚型为独立预后因素。

核心结论

  • CHER-Lob试验生存分析证实pCR和TILs的预后作用,并显示拉帕替尼联合曲妥珠单抗较曲妥珠单抗有更好结局的信号。

研究设计与样本

  • Cher-LOB随机II期研究纳入121例HER2阳性、II-IIIA期乳腺癌患者,设计特定方案收集RFS和OS数据。
  • 基线评估肿瘤浸润淋巴细胞(TILs)和PAM50内在分型。

主要发现

  • 中位随访9年,拉帕替尼联合曲妥珠单抗较曲妥珠单抗显示RFS改善趋势(HR 0.44,95%CI 0.18-1.05)。
  • 合并治疗组分析,pCR与RFS显著相关(HR 0.12,95%CI 0.03-0.49),与OS也显著相关(HR 0.12,95%CI 0.03-0.49)。
  • TILs与RFS显著相关(每增加1%,HR=0.978)。
  • 多因素分析中,Luminal-A亚型较其他PAM50内在亚型是RFS改善的显著独立预测因素(HR 0.29,95%CI 0.09-0.94,p=0.040)。

临床怎么用

  • pCR和TILs可作为HER2阳性早期乳腺癌新辅助治疗后的预后指标。
  • 拉帕替尼联合曲妥珠单抗双靶向新辅助治疗在生存结局上显示优于曲妥珠单抗单靶向的趋势信号。

局限性

  • 本研究为随机II期试验的事后生存分析,样本量121例。
  • 拉帕替尼联合曲妥珠单抗较曲妥珠单抗的RFS改善仅为趋势(95%CI上限跨越1)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The Cher-LOB randomised phase II study showed that the combination of lapatinib-trastuzumab plus chemotherapy increases pathologic complete response (pCR) rate compared with chemotherapy plus either trastuzumab or lapatinib. Here, we report the post hoc survival analysis as per treatment arm, pCR and biomarkers. METHODS: The Cher-LOB study randomised 121 patients with human epidermal growth factor receptor 2-positive, stage II-IIIA breast cancer. A specific protocol to collect recurrence-free survival (RFS) and overall survival (OS) data was designed. Tumour-infiltrating lymphocytes (TILs) and PAM50-intrinsic subtyping were evaluated at baseline. RESULTS: At 9-year median follow-up, a trend towards RFS improvement with lapatinib-trastuzumab over trastuzumab was observed (hazard ratio [HR] 0.44, 95% confidence interval [CI] 0.18-1.05). Combining treatment arms, pCR was significantly associated with both RFS (HR 0.12, 95% CI 0.03-0.49) and OS (HR 0.12, 95% CI 0.03-0.49). TILs were significantly associated with RFS (HR = 0.978 for each 1% increment). Luminal-A subtype was a significant and independent predictor of improved RFS as compared with other PAM50-based intrinsic subtypes at the multivariate analysis including the most relevant clinicopathologic variables (HR 0.29, 95% CI 0.09-0.94, p = 0.040). CONCLUSIONS: Cher-LOB trial survival analysis confirmed the prognostic role of pCR and TILs and showed a signal for a better outcome with lapatinib-trastuzumab over trastuzumab. TRIAL REGISTRATION: NCT00429299.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Guarneri V, Dieci MV, Griguolo G, et al. Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial. Eur J Cancer. 2021. PMID: 34153715. doi:10.1016/j.ejca.2021.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。